Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2
| dc.creator | Bulterys, Philip L. | |
| dc.creator | Garamani, Natasha | |
| dc.creator | Stevens, Bryan | |
| dc.creator | Sahoo, Malaya K. | |
| dc.creator | Huang, Chun Hong | |
| dc.creator | Hogan, Catherine A. | |
| dc.creator | Zehnder, James | |
| dc.creator | Pinsky, Benjamin A. | |
| dc.date.accessioned | 2020-08-31T17:08:52Z | |
| dc.date.available | 2020-08-31T17:08:52Z | |
| dc.date.created | 2020-08 | |
| dc.description.abstractenglish | Background Numerous nucleic acid amplification tests, including real-time, reverse transcription PCR (rRT-PCR) and isothermal amplification methods, have been developed to detect SARS-CoV-2 RNA, including many that have received emergency use authorization (EUA). There is a need to assess their test performance relative to one another. Objectives The aim of this study was to compare the test performance of a high complexity laboratory-developed rRT-PCR EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene with other tests: the Atila isothermal amplification assay targeting the nucleocapsid (N) gene and open reading frame 1ab (ORF1ab), the Altona E and spike (S) multiplex, real-time RT-PCR, and the US Centers for Disease Control and Prevention (CDC) N1 and N2 rRT-PCRs. Study Design A diagnostic comparison study was performed by testing nasopharyngeal samples from persons under investigation for coronavirus disease 2019 (COVID-19). Assay performance was assessed by percent agreement and Cohen’s kappa coefficient. Results Positive percent agreement with the SHC EUA reference assay was 82.8 % (95 % confidence interval (CI) 65.0 to 92.9) for Atila, 86.7 % (95 % CI 69.7 to 95.3) for the Altona E and S targets, and 86.7 % (95 % CI 69.7 to 95.3) and 90.0 % (95 % CI 73.6 to 97.3), for the CDC N1 and N2 targets, respectively. All assays demonstrated 100 % negative percent agreement. Kappa coefficients ranged from 0.86 to 0.92, indicating excellent agreement. Conclusions Performance was comparable among the SARS-CoV-2 nucleic acid amplification methods tested, with a limited number of discrepancies observed in specimens with low viral loads. | spa |
| dc.format.extent | 4 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.jcv.2020.104427 | spa |
| dc.identifier.issn | 1386-6532 | spa |
| dc.identifier.other | https://www.sciencedirect.com/science/article/pii/S1386653220301694?via%3Dihub | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/12473 | |
| dc.language.iso | eng | spa |
| dc.publisher | Journal of Clinical Virology | spa |
| dc.rights.accessrights | info:eu-repo/semantics/embargoedAccess | spa |
| dc.rights.local | Acceso restringido | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | SARS-CoV-2 | spa |
| dc.subject | Coronavirus | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.subject.lemb | Diagnostics | spa |
| dc.title | Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2 | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Comparison-of-a-laboratory-developed-test-targeting-the-env_2020_Journal-of-.pdf
- Tamaño:
- 171.96 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Documento reservado
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
